PACB 📈 Pacific Biosciences of - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US69404D1081
PACB: Sequencing Systems, Consumable Products, Reagent Kits, Binding Kits
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California. Web URL: https://www.pacb.com
Additional Sources for PACB Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PACB Stock Overview
Market Cap in USD | 603m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 2010-10-27 |
PACB Stock Ratings
Growth 5y | -59.9% |
Fundamental | -49.5% |
Dividend | - |
Rel. Strength Industry | -1651 |
Analysts | 3.87/5 |
Fair Price Momentum | 1.67 USD |
Fair Price DCF | - |
PACB Dividends
No Dividends PaidPACB Growth Ratios
Growth Correlation 3m | 41.1% |
Growth Correlation 12m | -55.5% |
Growth Correlation 5y | -36.1% |
CAGR 5y | -17.76% |
CAGR/Mean DD 5y | -0.28 |
Sharpe Ratio 12m | -0.79 |
Alpha | -134.23 |
Beta | 2.29 |
Volatility | 103.31% |
Current Volume | 10838.3k |
Average Volume 20d | 9308.4k |
What is the price of PACB stocks?
As of December 21, 2024, the stock is trading at USD 1.97 with a total of 10,838,282 shares traded.
Over the past week, the price has changed by +0.51%, over one month by +14.53%, over three months by +7.95% and over the past year by -79.82%.
As of December 21, 2024, the stock is trading at USD 1.97 with a total of 10,838,282 shares traded.
Over the past week, the price has changed by +0.51%, over one month by +14.53%, over three months by +7.95% and over the past year by -79.82%.
Is Pacific Biosciences of a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Pacific Biosciences of (NASDAQ:PACB) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.52 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PACB as of December 2024 is 1.67. This means that PACB is currently overvalued and has a potential downside of -15.23%.
Probably not. Based on ValueRay Fundamental Analyses, Pacific Biosciences of (NASDAQ:PACB) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -49.52 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PACB as of December 2024 is 1.67. This means that PACB is currently overvalued and has a potential downside of -15.23%.
Is PACB a buy, sell or hold?
Pacific Biosciences of has received a consensus analysts rating of 3.87. Therefor, it is recommend to buy PACB.
Pacific Biosciences of has received a consensus analysts rating of 3.87. Therefor, it is recommend to buy PACB.
- Strong Buy: 6
- Buy: 1
- Hold: 8
- Sell: 0
- Strong Sell: 0
What are the forecast for PACB stock price target?
According to ValueRays Forecast Model, PACB Pacific Biosciences of will be worth about 1.8 in December 2025. The stock is currently trading at 1.97. This means that the stock has a potential downside of -8.12%.
According to ValueRays Forecast Model, PACB Pacific Biosciences of will be worth about 1.8 in December 2025. The stock is currently trading at 1.97. This means that the stock has a potential downside of -8.12%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 3 | 53.3% |
Analysts Target Price | 13.8 | 599% |
ValueRay Target Price | 1.8 | -8.1% |